



CHARACTERIZING MEDICATION ADHERENCE TO AN ORAL 




Geetha Sankar Narayanan Iyer 
 
 
A thesis submitted to John Hopkins University in conformity with the requirements for 











Medication non-adherence is a major contributor to suboptimal control of chronic diseases. 
Its consequences include inferior clinical outcomes as well as unnecessary health care 
costs. Group based trajectory models (GBTM), a type of finite mixture model, can be used 
to identify distinct trajectories of medication adherence among the patient population. It 
models adherence as a longitudinal parameter.  
Objective 
To characterize patterns of medication adherence among adult patients in the first year of 
initiating metformin using group based trajectory models, compared to the traditional 
summary measure of proportion of days covered. 
Methods 
We identified patients who initiated metformin, an oral glucose lowering drug, between 1st 
January to 31st December, 2011 from pharmacy prescription claims in Truven MarketScan 
Commercial Claims and Encounter database and followed them for a period of 360 days. 
We evaluated the number of days covered by metformin in 12 30 day periods and generated 
12 monthly indicators to indicate whether that month was fully covered (defined as 24 or 
more days out of the 30 days). We modeled trajectories using group based trajectory 
models (2 to 6 groups) using these monthly indicators. We also calculated a traditional 
summary measure, proportion of days covered (PDC). We used Bayesian Information 
Criterion (BIC), posterior probabilities and clinical relevant interpretations in order to 
decide the best fit model. Additionally, we compared the accuracy of prediction of 




Among 77,279 patients who initiated metformin in 2011, we found that the 5 and 6 group 
model performed comparably. Overall the 6 group trajectory model summarized long term 
adherence best (C statistic 0.951) and PDC categorized as 80% or more (value of 1) and 
less than 80% (value of 0) summarized adherence worst (C statistic 0.767). However, 
keeping in the mind the relevance of clinical interpretation, we chose the 5 group model to 
be best fit model.   
Conclusion 
Group based trajectory models can be used to summarize medication adherence more 
accurately than proportion of days covered. This newer method can be used by payers, 
clinicians and researchers in order to identify groups of patients with distinct adherence 
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Healthcare costs in the United States have been increasing at an alarming rate 
over the last few decades. Not surprisingly, a large portion of the spending is allocated 
towards patients with chronic diseases. A recent publication by the Non-communicable 
Disease Risk Factor Collaboration estimated the direct annual economic burden of 
diabetes mellitus globally in 2014 to be $825 billion, with the United States ($105 
billion) coming second only to China ($170 billion).1 Similarly, the total direct and 
indirect cost of cardiovascular disease and stroke in the United States in 2010 was 
calculated to be $315.4 billion.2 Optimal disease management and control of these 
patients not only requires good medical care on the side of the healthcare providers but 
also effective implementation of self-management on part of the patients.  
Medication non-adherence is a major contributor to poor control of chronic 
diseases. The consequences of non-adherence include inferior clinical outcomes as well 
as unnecessary health care costs. A paper evaluating the economic benefit of medication 
adherence showed that for every additional dollar spent on adhering to a prescribed 
medication, medical costs would be reduced by $7.10 for diabetes, $5.10 for 
hypercholesterolemia, and $4 for hypertension.3 A systematic review by Bitton et al4 
observed that high adherence to statins for secondary prevention of coronary artery 
disease reduced annual hospitalization costs by 10%-17%. Non-adherence to medications 
among patients with type 2 diabetes mellitus is associated with worse control of 
intermediate risk factors, higher odds of hospitalization and healthcare costs and 
increased risk of mortality.5 6  
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Medication adherence depends on a complex interplay between patients’ 
characteristics, their behavior and environment, the healthcare system and the disease.7 
Traditionally, the norm in adherence research has been to classify patients as ‘adherent’ 
and ‘non-adherent’ based on a threshold, often taken as 80% days covered by the 
medication.8 It is increasingly being recognized that these broad classes are an 
oversimplification and there is potential to improve upon them. There is a large body of 
ongoing research aimed at designing interventions to improving adherence, ranging from 
empowering the patients themselves with mHealth initiatives9 to involving pharmacists 
and other healthcare workers to be part of the solution.10-12 However, when it comes to 
actual implementation, it has been clear for a while that the one size does not fit all. In 
order to individualize the interventions, we must go beyond categorizing patients as 
adherent and non-adherent. Two individuals who have been adherent to a drug 50% of 
the time could have different longitudinal patterns; one might be adherent only for the 
first few months of a treatment while the other could be intermittently adherent 
throughout the treatment course. Understanding and identification of these patterns can 
give us clues for customizing interventions that can have the maximum impact.   
Group based trajectory models, as conceptualized by Nagin et al13 14 and used 
extensively in social and behavioral research, identify distinct trajectory patterns of any 
exposure within the data without external specification of the structure of the groups. 
This method had recently been used by Franklin et al to model medication adherence to 
statins as a longitudinal parameter.15 The rationale was that there might be meaningful 
subgroups in the population that follow distinct adherence trajectories which are not 
identifiable ex ante on the basis of some measured characteristics such as age, gender, 
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education, etc. and that there are actual distinctive adherence patterns in the population; 
always adherent vs. adherent for the first few months vs adherent intermittently vs. never 
adherent. 
Diabetes mellitus is common chronic metabolic disorder which affects a large 
portion of the population globally. A recent statistic observed that the prevalence of type 
2 diabetes mellitus and pre-diabetes in the overall population of the United States in 
2011-2012 was 14.3% (95% CI 12.2% -16.8%) and 38% (95% CI 34.7% - 41.3%) 
respectively.16 Despite the availability of many drug classes and frequently updated 
international and national guidelines, a substantial proportion of the population fails to 
achieve their glycemic goals. While several factors may contribute to this, lack of 
adherence to the recommended treatment is considered an important factor. Several 
studies have shown that medication adherence to oral glucose lowering drug ranges from 
65-85% while adherence to insulin ranges from 60-80%17 and that poor adherence is 
associated with worse glycemic control.18  
I propose to characterize adherence to metformin, a first line oral treatment for 
type 2 diabetes, using group based trajectory models as compared to the traditional 
measurement, proportion of days covered, in patients who have newly initiated this drug.  
 
  





Specific aim 1. To characterize patterns of medication adherence among adult patients in 
the first year of initiating metformin using group based trajectory models. 
Hypothesis: There are several distinct trajectories of medication adherence in the 
population, which can be modeled as a longitudinal process using group based trajectory 
models. 
 
Specific aim 2. To compare group based trajectory models and the proportion of days 
covered as summary measures of medication adherence 
Hypothesis: Group based trajectory models will summarize adherence better than a 
traditional measurement, proportion of days covered. 
 
Specific aim 3. To identify the factors associated with the distinct trajectories, including 
patient demographics, healthcare utilization, comorbidities, and polypharmacy.  
Hypothesis: Younger age, higher burden of prescription drugs and presence of certain 










We used the 2010-2012 Truven MarketScan Commercial Claims and Encounters 
database. The MarketScan database contains data from over 75 million patients including 
active employees, early retirees, Consolidated Omnibus Budget Reconciliated Act 
(COBRA) continues and dependents insured by employer-sponsored plans in the United 
States. The dataset captures individual level information about their demographic 
characteristics, clinical services utilization, expenditures, enrollment across inpatient, 
outpatient and prescription drug services. We used national drug codes (NDCs) from 
RED BOOK™ available from Truven Health Analytics to identify the prescription drugs 
in the pharmacy claims data.  
Cohort derivation 
The study population included all patients who newly initiated metformin 
monotherapy in the year 2011 and had one year complete follow up information (Figure 
1).  We chose metformin as our drug of interest as it is well established as the first line 
drug recommended by the American Diabetes Association.19 We identified patients who 
filled their first prescription for metformin from a retail pharmacy between 1st January 
and 31st December, 2011 from the outpatient pharmacy claims data. Index date was 
defined as the date of the first prescription claim. To make sure that the included patients 
were incident users, we only included those who had continuous enrollment in the 
database in the 12 months preceding the index date with no prescription of any glucose 
lowering medications (oral or injectable) during that time. 
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We excluded patients filling index prescriptions by mail since their adherence 
may differ from those using retail pharmacies.20 We required that complete information 
about age, sex, fill date, day supply and source of pharmacy fill (whether retail or mail 
pharmacy) be available. In order to plot the trajectories of medication adherence for one 
year, we included patients who had 12 months continuous enrollment after the index date 
(regardless of subsequent prescription refill). We excluded patients switching drug 
classes or starting dual therapy during follow up. 
Adherence measures 
We summarized adherence to metformin using two methods - the proportion of 
days covered (PDC) and the group based trajectory models (GBTM). To calculate these 
measures, we followed patients for the next 360 days (12 ‘months’ of 30 days each) after 
the index date and extracted all dates of prescription fill along with the number of days’ 
supply dispensed. If the pharmacy fill for the drug on any given day was more than 180 
days, we truncated the fill at 180 days.  
We created a separate dataset where an array of binary indicators was generated, 
one for each day of the follow up. It was coded as 1 if that day was covered by metformin 
and 0 otherwise, using the above extracted information. If the subsequent fill occurred 
before the end of days’ supply for the previous fill, we assumed that the newly dispensed 
drug was used after the prior fill was exhausted. We then created a summary ‘monthly 
indicator’ for each 30 day period (1 – 30 days, 31 to 60 days and so forth) with 0 
indicating less than 80% coverage translating to 23 days or less coverage of drugs for that 
month and 1 indicating 80% or more coverage translating into 24 days or more coverage 
for the month. We chose the cut off of 80% for categorizing adherence as it has been 
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widely accepted as the threshold for optimal adherence in research. It is also the coverage 
which is recommended by the WHO to be reached for achieving potential benefits of 
diabetes medications.8 These binary ‘monthly indicators’ for 12 months were the 
variables of interest which were modelled in the group based trajectory model. 
Additionally, we calculated the traditional summary measure of adherence i.e. the 
proportions of days covered (PDC) for the entire 360 day period as well as dichotomized 
PDC into 80% or more being fully adherent and less than 80% being non-adherent. 
Group based trajectory model 
We used group based trajectory model (GBTM), a type of latent class analysis 
model, to classify patients according to their medication adherence trajectory. The 
advantage of the group based trajectory models over conventional growth models is that 
instead of assuming everyone follows a similar adherence trajectory with a population 
mean adherence trajectory, it assumes that there are clusters of distinctive trajectories of 
medication adherence that reflect unique etiologies or behaviors. Not everyone’s 
adherence patterns will increase over time; some might stay the same, some might 
decrease and GBTM allows for this freedom. Standard growth curve models aim to 
identify the factors which account for individual variability about the population’s mean 
adherence trajectory while the GBTM frames inferences based on the trajectory groups 
i.e. what factors distinguish group membership. An important assumption of the model is 
of conditional independence.21 It states that repeated measures on the same individual are 
independent within the same trajectory and the within person correlation structure is 
explained completely by their trajectory.  
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We explored the data and fit 5 separate trajectory models, with the number of 
groups ranging from 2 to 6. We limited the maximum number of trajectory groups to 6 as 
we felt it would be difficult to interpret the clinical significance and usefulness of too 
many trajectories. To allow the trajectories to be flexible and not be constrained by 
symmetry, we added the square and cubic terms of time to the trajectory. Here the 
trajectory is allowed more than one peak or trough and can turn multiple times. The 
output of a group-based trajectory model includes estimated probabilities of group 
membership for each individual, proportion of entire population in each group and an 
estimated trajectory curve over time for each group. We used a Stata version 1322 plugin, 
with the command traj, for estimating group based trajectory model as developed by 
Jones and Nagin.23 Maximum likelihood is used for the estimation of the model 
parameters.  
Model diagnostics 
Nagin et al has suggested the use of average posterior probability (APP) of 
assignment as a diagnostic tool to evaluate the accuracy of the group membership 
probabilities. The posterior probability is the probability that an individual with a specific 
adherence pattern belongs to a specific trajectory group.21 The output of the model 
creates a separate variable for each group which contains the probability of being in that 
group for every individual in the population. For example, consider that we are modelling 
a 4 group trajectory model and we have posterior probabilities generated for a patient as 
0.2 for group 1, 0.6 for group 2, 0.3 for group 3 and 0.9 for group 4. Here, the patient has 
the highest probability of being in group 4 (0.9 vs 0.2, 0.3 and 0.6) and hence, the patient 
will be assigned to group 4. Ideally the APP should as close to 1 as possible. An average 
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posterior probability of 0.7 is considered as a minimum threshold for all groups. We 
calculated the mean/standard deviation as well as median/inter quartile range of the 
posterior probabilities of each group. The Bayesian Information Criterion (BIC) was also 
used to select the model with the best fit as recommended in the trajectory literature,13 
with higher score indicating better fit. Ultimately, the model selection was done using 
both the above mentioned criteria as well as clinical interpretation and usefulness of the 
generated trajectories. 
Comparing adherence summaries 
 We compared different measurement methods i.e. the total PDC over follow up, 
dichotomized PDC and GBTM having 2 to 6 distinct groups to see which method best 
summarized the observed medication adherence. We assigned a separate adherence 
summary for every patient and person month (total 12 months in the follow up). In case 
of total PDC and dichotomized PDC, the summary measure was the same across person 
months but varied for each patient. In case of the group based trajectory models, the 
adherence summary measures were different across the person-months but were the same 
for all members of the same group. We combined the summary measures for all person-
months that were fully covered (monthly indicators were 1) and those that were not 
covered by metformin (monthly indicators were 0) and calculated the mean, median and 
the interquartile range. The summary measures for the months that were fully covered 
needed to approximate 1 and the months that were not fully covered needed to 
approximate 0. We used C-statistics to see how well the estimated summary measures 
(“test values”) compared to the observed (“the gold standard” measure of binary 
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indicators indicating more than 80% adherence during the month). A C-statistic of 1.0 
indicates perfect association while a value of 0.5 indicates no association. 
Covariates 
We examined the distribution of certain covariates in the study population as well 
as across the trajectory groups determined by the best fit model. The demographic 
covariates included age, sex, region in the US and patient’s health plan. As polypharmacy 
has been shown to influence adherence, we calculated the number of unique drugs filled 
in the 6 months before index date of prescription. Hertz24 et al and Kirkman25 et al 
observed that the presence of cardiovascular diseases such as hypertension and 
hyperlipidemia, either identified by ICD-9 codes or by their prescription drug fill, were 
associated with higher adherence to glucose lowering drugs and depression was 
associated with reduced adherence. Additionally, we noted the details of the initial 
metformin therapy – amount of copay, whether a brand or generic was initiated, which 
formulation – immediate or extended release was initiated. These data are composed of 
de-identified patient information, hence it was considered exempt research by the 
Institutional Review Board of Johns Hopkins University. 
 
  




A total of 77,297 patients who initiated metformin monotherapy in 2011 were 
included in the study. The distribution of baseline characteristics of the included patients 
is given in Table 1. The majority of the patients belonged to the age group of 45 to 54 
years of age (32%), were males (59%) and lived in the southern region of United States 
(46%). The average number of unique prescriptions filled out in the last 6 months was 6 
(±3.9) with a wide range of 1 to 50. A substantial proportion of patients had filled a 
prescription for cholesterol lowering drugs (35%) and anti-hypertensives (beta blockers 
16%, ACE inhibitors/ARBs 35%). One in five patients had filled a prescription for an 
antidepressant in the 6 months prior to index date. Keeping in line with the prescription 
fills, almost one third of the patients had a physician’s visit with a diagnosis of 
hypertension, hyperlipidemia and depression in the 6 months before index prescription. 
 Group based trajectory models 
 Figure 2 shows the various distinct trajectories identified by the group based 
trajectory models (with groups ranging from 2 to 6). We can see that the probability of 
adherence varies across time for all patients, which is captured within the trajectories. 
Table 1 details the distribution of patients across the different groups for all models. For 
example, in the 2 group model, the patients are categorized into two groups, one with 
high probability of adherence, which includes 41.8% patients and one with rapidly 
declining probability of adherence, including 58.2% of patients. As the number of groups 
are increased (2 through 6), we observe that the extreme groups (almost fully adherent 
and non-adherent after index prescription) persist and many patients are redistributed in 
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the middle groups where distinct adherence patterns emerge. With the 6 group model, we 
observed that 16.3% of the patients were almost always adherent, Group 1; 14.9% of the 
patients were found to be intermittently adherent through of the year, Group 2; adherence 
of 12.8% of the patients declined in the first few months but then increased slightly 
(occasionally adherent) over the next 6 months, Group 3; 11.9% of the patients had 
slowly declining adherence after the index prescription was filled, Group 4; 21.3% of the 
patients had slow declining adherence, Group 5; and 22.8% were non-adherent after the 
first fill, Group 6 (Figure 2, Panel E).  
We assessed the model with the best fit using BIC values and the average 
posterior probabilities of being in each group. These details are given in Table 2 and 3. 
We observed that the BIC values was the largest for the GBTM specifying 6 groups. For 
each of the group based trajectory models (with 2 group, 3 group, 4 group etc.), we 
calculated the average posterior probability of being in each group. The APP was higher 
than the threshold of 0.7 across all groups and all models. We saw that the patients 
assigned to the consistently extreme groups (consistently adherent vs. non-adherent after 
index prescription) had the highest APP values, nearing 1, while the patients assigned to 
other groups had lower APP values in models specifying 3 to 6 groups.   
Comparing adherence summaries 
 We compared the different methods of summarizing adherence as given in table 
2. We calculated the average summary measures for each method separately, for months 
which were categorized as non-adherent (less than 23 days coverage of the 30 day period) 
and the months which were categorized as adherent (24 or more days coverage of the 30 
day period). There were 496,805 person-months in the one year follow up period which 
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was not fully covered by metformin. In these months, better performing adherence 
summaries would have low values, close to 0 – showing that the summarized adherence 
was similar to the observed adherence from the data. There were 430,759 person-months 
in the one year follow up period which was fully covered by metformin. In these months, 
better performing adherence summaries would have values close to 1 (estimated closer to 
the observed). For example, for person-months fully covered by metformin where the 
observed or ‘true’ probability of being adherent is 1, group based trajectory models with 
2 groups estimated that the average probability of being adherent was 0.73±0.23 
compared to PDC overall which estimated that the average probability of being adherent 
was 0.77±0.25. Similarly, for person-months not covered by metformin where the 
observed or ‘true’ probability of being adherent is 0, group based trajectory models with 
2 groups estimated that the average probability of being adherent was 0.23±0.26 
compared to PDC overall which estimated that the average probability of being adherent 
was 0.36±0.22.  
Among the conventional methods of summarizing adherence, we observed that 
overall PDC approximated 1 (0.77±0.25) in fully covered person-months but performed 
poorly in non-covered person months and the PDC categorized into adherent and non-
adherent (0 or 1) performed very well for non-adherent months (0.06 ± 0.24) but fared 
poorly in fully covered person-months (0.59±0.49). Group based trajectory models, even 
the 2 group model, summarized adherence better for both covered and non-covered 
person months compared to conventional methods and further improvement was seen as 
the number of groups increased from 2 to 6. The C-statistic, which compared the ‘test’ 
values to the ‘gold’ standard, improved as the number of groups specified were increased 
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in group based trajectory models. Overall the 6 group trajectory model summarized long 
term adherence best (C=0.951) and binary PDC summarized adherence worst (C=0.767).  
The performance of the 5 group and 6 group models were comparable. However, 
the selection of the best fit model was not only based on statistical parameters but also its 
appropriate clinical interpretation. We decided that the distinct trajectories generated by 5 
group model captured the underlying medication adherence behaviors which could 
potentially be applied to identifying appropriate interventions and be clinically 
meaningful. In the 5 group model, we observed that around one fourth of the patients 
(24.8%) were almost always adherent, 12.9% of the patients were intermittently adherent 
through of the year, 12% of the patients had slowly declining adherence after the index 
prescription was filled, 24.7% of the patients had rapidly declining adherence and 22.9% 
were non-adherent after the first fill.  
 Characteristics across the 5 groups  
When we assessed the distribution of the baseline characteristics for the 5 groups, 
we observed that the group which was poorly adherent to metformin (group 5) had a 
larger proportion of patients in the age group of 18 to 34 years, were more likely to be 
male and did not have any prescription filled for more than 60 days (Table 4). The 
number of unique prescription filled in the last 6 months were similar across the 5 groups. 
The group containing patients who were almost always adherent (Group 1) had a higher 
proportion of prescription fills for cholesterol lowering drugs, anti-hypertensives such as 
beta blockers, ACE inhibitors and angiotensin receptor blockers, which falls as the 
groups become less adherent (Group 2 to 5). When we observe the comorbidities 
identified, we see a similar pattern. The patients in Group 1 are more likely to have 
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hypertension and hyperlipidemia versus group 5. The proportion of patients in Group 1 
(almost always adherent) who had an outpatient visit for depression in the 6 months 
before index prescription was lower than in Group 5 (poorly adherent). The proportion of 
patients on antidepressants were comparable across the groups.       
  





The present study determined that the group based trajectory models summarize 
adherence more accurately than the conventional adherence summary measure, 
proportion of days covered. Our results demonstrate that there are distinct patterns of 
medication adherence to metformin in the population which can be further examined and 
understood. Among the number of groups evaluated, the 5 group model was selected as 
the best fit model on the basis of clinical interpretation and statistical considerations.  
As suggested by Nagin et al, we used many criteria to select the model with the 
best fit including BIC and average posterior probabilities.21 We saw that the average 
posterior probabilities were almost perfect (near 1) with the 2 group model and continued 
to be high (more than 0.9) as the number of groups specified increased. This 
demonstrates that the probability of being in the assigned group was high among patients 
indicating that group assignment was largely accurate. Due to the large sample size of the 
study, it was expected that the model fit would improve even if we empirically tested 
more groups (7 and more). However, the clinical meaning of a large number of groups 
would be ambiguous. Hence we limited the number of groups to 6.  
Conventionally, methods to measure adherence are classified as subjective or 
objective.26 27 The studies which utilize pharmacy or administrative claims data use 
pharmacy fill dates reported as part of the claims process to calculate adherence. Since 
group based trajectory models were first evaluated by Franklin et al in 2013 to summarize 
medication adherence to statins,15 other researchers have used this method for assessing 
adherence to anti-glaucoma medications in a managed care population,28 heart failure 
medications using pharmacy claims29 and biologics for psoriasis.30  
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The area of adherence research has been flooded with interventions aimed at its 
improvement. Interventions can be classified as educational, either one-on-one or group 
sessions; behavioral such as packaging and dose modifications, and mail or telephone 
reminders; affective such as counselling sessions, home visits etc;31 economic or 
multifaceted, involving multiple interventions.32 A recent systematic review done by 
Saptoka and colleagues showed that majority of the interventions aimed at type 2 
diabetes mellitus patients were educational and behavioral in nature.32 However, only a 
small number of interventions were effective, which were largely multifaceted in their 
approach. The trend towards precision medicine can also be applied to medication 
adherence with a move towards individualizing interventions based on the observed 
adherence patterns.  
We noted that modeling adherence using group based trajectory models may help 
identify broad classes of patients as well as certain interventions which may selectively 
benefit certain populations. These interventions can be empirically tested for their 
effectiveness. In our results, we observed that around a fourth of the patients were highly 
adherent. While these patients were more likely to have prescriptions for other chronic 
diseases, they may not require any interventions except regular interactions and follow up 
with healthcare professionals. The patients who are intermittently adherent after the first 
few months might benefit from a combination of reminder messages from the pharmacy 
as well as sessions of diabetes self-management education while patients who are almost 
always non-adherent may favor affective interventions such as one on one counselling 
sessions as well as home visits. We can also use GBTM identify patient and disease 
factors associated with specific trajectories. If patients who are almost always non-
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adherent are found to have many comorbidities and active prescriptions, they might 
benefit by specialized pharmacy services such as compliance or calendar packaging.33 
For example, a study evaluating an outpatient pharmacy clinical service (OPCS) program 
targeting non-adherent diabetes mellitus and coronary artery disease patients showed 
significant improvement in medication persistence levels.34 
Some foundational work has been done in exploring how the new adherence 
summary measure can be used in research as well as in clinical practice. Franklin et al 
have shown that the adherence summarized by GBTM is a better predictor of future 
adherence than the traditional methods or even high dimensional propensity scores.35 36 
Furthermore, these models have been evaluated for their ability to predict future clinical 
outcomes. A study done among statin users and future cardiovascular events observed 
that better predictive performance with trajectory models compared to proportion of days 
covered.37  
Curkendall et al38 studied the predictors of medication adherence among patients 
with type 2 diabetes mellitus and found that around 45% of total patients were adherent 
(defined as more than 80% coverage) over one year of follow up. Adherence was found 
to be higher among males, older age, living in non-Southern states, with mail order use 
and lower levels of cost sharing. Hertz et al24 found that around 37% of patients 
discontinued pharmacotherapy within 12 months of initiation. Our findings that group 
with high levels of adherence had larger proportion of patients with hypertension and 
hyperlipidemia and fewer patients on antidepressants corroborated results observed by 
Hertz et al.24  
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There were a few limitations of the study. Proportion of days covered is a 
measure of drug coverage with an assumption that coverage is a proxy for adherence. 
However, we cannot be certain that the patient is actually taking the medications as per 
the physicians’ instructions. Additionally, there were a large proportion of index 
prescriptions filled for 60 to 90 days. In these cases, the patients are credited with being 
in possession for more days because of the bigger dispensing. As we are taking the first 
prescription fill as our starting point, the patients who were actually prescribed metformin 
by the physician but failed to fill it were missed. In fact, they might the patients who need 
the most effective interventions. We also only analyzed patients who were prescribed 
metformin alone, which is a subset of all diabetic patients. Nevertheless, the aim of the 
study was primarily to evaluate the performance of group based trajectory model rather 
than draw causal associations and conclusions.  
Diabetes mellitus has been a prominent non-communicable disease for many 
decades. Evidence suggests that the epidemic may have plateaued with fewer new 
incident cases being diagnosed16 but it still leaves us with a large population with high 
economic and healthcare burden. New drugs are constantly being designed with an intent 
to satisfy unmet needs in the population but optimal utilization of currently available 
drugs is vital. The place of group based trajectory models in the field of adherence 
research need to be investigated further. We intend to extend this study further into 
looking at the association of different adherence patterns with clinical outcomes as well 
as understand how patterns of medication adherence may change with time dependent 
factors. Given the promising preliminary research, this method can be used in order to 
empirically test effectiveness of interventions, aid clinicians and payers in identifying 
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patients who are poorly adherent to medications earlier and ultimately reduce healthcare 
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Table 1. Characteristics of the overall study population (n=77297) 
Characteristics Percentage  
Age, % 
18 to 34 years 
35 to 44 years 
45 to 54 years 






Male sex, % 59.3 












Index prescription – copay amount, % 
$0 
$0.1 to $9.99 
$10 to $19.99 












Index prescription – day supply, % 
Less than 15 days 
16 to 30 days 
31 to 60 days 
61 to 90 days 













Average number of unique drugs filled in the 
last 6 months 
Mean ±SD (Range) 
 
6 ± 3.9 
(1 – 50) 
Prescriptions filled in last 6 months, % 
Cholesterol lowering drugs 
















SD – Standard deviation, ACE – Angiotensin converting enzyme, ARB – Angiotensin receptor blocker 
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Table 2. Distribution of patients across groups in various  






of patients  
Posterior probability of being in the group 
Mean (±SD) Median (IQR) 
2 group 
model 
Group 1 41.9 0.98 (± 0.07) 1.0 (1.0 – 1.0) 
Group 2 58.1 0.98 (± 0.07) 1.0 (1.0 – 1.0) 
3 group 
model 
Group 1 28.1 0.96 (± 0.09) 1.00 (0.98 – 1.00) 
Group 2 30.8 0.92 (± 0.12) 0.98 (0.85 – 0.99) 
Group 3 41.1 0.95 (± 0.10) 0.99 (0.96 – 1.00) 
4 group 
model 
Group 1 27.9 0.95 (± 0.10) 0.99 (0.97 – 1.00) 
Group 2 16.7 0.86 (± 0.16) 0.95 (0.75 – 0.99) 
Group 3 16.2 0.87 (± 0.15) 0.96 (0.81 – 0.98) 
Group 4 39.2 0.92 (± 0.15) 0.99 (0.92 – 1.00) 
5 group 
model 
Group 1 24.8 0.96 (± 0.1) 0.99 (0.98 – 1.00) 
Group 2 12.9 0.85 (± 0.17) 0.94 (0.74 – 0.99) 
Group 3 12.0 0.84 (± 0.16) 0.92 (0.71 – 0.98) 
Group 4 27.4 0.93 (± 0.13) 0.99 (0.93 – 1.00) 
Group 5 22.9 0.9 (± 0.03) 0.9 (0.9 – 0.9) 
6 group 
model 
Group 1 16.3 0.89 (± 0.08) 0.92 (0.92 – 0.92) 
Group 2 14.9 0.92 (± 0.14) 0.99 (0.91 – 1.00) 
Group 3 12.8 0.9 (± 0.14) 0.97 (0.84 – 0.99) 
Group 4 11.9 0.84 (± 0.15) 0.88 (0.71 – 0.98) 
Group 5 21.3 0.9 (± 0.1) 0.94 (0.91 – 0.97) 
Group 6 22.8 0.92 (± 0.01) 0.92 (0.92 – 0.92) 
 
GBTM – Group based trajectory model, IQR – interquartile range, SD – Standard deviation 
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Table 3. Table comparing the summary values of different trajectory models with 2 to 6 groups with traditional measures  
 
Model 
Fully adherent months  
(N = 430,759) 
Non-adherent months  
(N = 496,805) 
C statistic BIC 
Mean (SD) Median (IQR) Mean (SD) Median (IQR) 
PDC 0.77 (0.25) 0.86 (0.61 - 0.98) 0.36 (0.22) 0.30 (0.14 - 0.53) 0.876 
- 
PDC – binary 0.59 (0.49) 1.00 (0.00 - 1.00) 0.06 (0.24) 0.00 (0.00 - 1.00) 0.767 - 
GBTM - 2 groups 0.73 (0.23) 0.81 (0.77 - 0.85) 0.23 (0.26) 0.10 (0.09 - 0.26) 0.891 -421350.40 
GBTM - 3 groups 0.77 (0.24) 0.90 (0.65 - 0.92) 0.20 (0.25) 0.03 (0.02 - 0.39) 0.925 -396895.14 
GBTM - 4 groups 0.78 (0.23) 0.92 (0.61 - 0.93) 0.18 (0.25) 0.03 (0.02 - 0.34) 0.935 -388537.95 
GBTM - 5 groups 0.80 (0.23) 0.92 (0.68 - 0.94) 0.16 (0.24) 0.05 (0.00 - 0.22) 0.946 -381773.23 
GBTM - 6 groups 0.81 (0.23) 0.88 (0.72 - 1.00) 0.16 (0.25) 0.00 (0.00 - 0.24) 0.951 -379752.27 
 
PDC – Proportion of days covered; GBTM – Group based trajectory models; SD – standard deviation; IQR – Interquartile range;  
BIC – Bayesian Information Criterion 
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Table 4. Characteristics of the study population according to the 5 group trajectory model  











18 to 34 years 
35 to 44 years 
45 to 54 years 


























Male sex, % 50.1 55.3 57.6 63.3 67.8 




































Index prescription – copay amount, % 
$0 
$0.1 to $9.99 
$10 to $19.99 












































Index prescription – day supply, % 
Less than 15 days 
16 to 30 days 
31 to 60 days 
61 to 90 days 































Number of unique drugs filled in the 
last 6 months 












(1 – 41) 
 
5.7±3.9 
(1 – 50) 
   
28 
 










Prescriptions filled in last 6 months, % 
Cholesterol lowering drugs 





















































SD – Standard deviation, ACE – Angiotensin converting enzyme, ARB – Angiotensin receptor blocker 
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VIII.  Figures 
 
Figure 1. Derivation of study cohort  
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Figure 2. Medication adherence trajectories using 2 to 6 groups showing both predicted 
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Panel B. Three groups
Group 1 - 28.1%
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